MedTrace Logo

Mobilization of Endothelial Progenitor Cells and Aspirin

NCT02674958 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-01-17

No results posted yet for this study

Summary

Aspirin at doses used during acute myocardial infarction may inhibit the mobilization of endothelial progenitor cells (EPCs).

Conditions

  • Hypertrophic Obstructive Cardiomyopathy

Interventions

DRUG

Aspirin

Aspirin 325mg bolus followed by 162mg daily until day 7 post alcohol septal ablation

Sponsors & Collaborators

  • Ottawa Heart Institute Research Corporation

    lead OTHER

Principal Investigators

  • Aun-Yeong Chong, MD, MRCP · OHIRC

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2022-04-01
Completion
2022-04-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02674958 on ClinicalTrials.gov